Oncology

Using Media to Promote Public Awareness of Early Detection of Kaposi's Sarcoma in Africa
Miriam Laker-Oketta, Lisa M Butler, Philippa Kadama-Makanga, Robert Inglis, Megan Wenger, Edward Katongole-Mbidde, Toby Maurer, Andrew Kambugu, Jeffrey N Martin

medRxiv 2019.12.11.19013649; doi: https://doi.org/10.1101/2019.12.11.19013649
TG-Interacting Factor 1 expression quantitatively impacts survival in acute myeloid leukemia
Ling Yan, Julie A. Means-Powell, Danko Martincic, Vladimir D. Kravtsov, Yu Shyr, John P. Greer, Utpal P. Dave, Mark J. Koury, David Wotton, Rizwan Hamid, Stephen J. Brandt

medRxiv 2020.02.04.20020537; doi: https://doi.org/10.1101/2020.02.04.20020537
Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival
Mark Jesus M Magbanua, Lamorna Brown-Swigart, Hsin-Ta Wu, Gillian L Hirst, Christina Yau, Denise M Wolf, Antony Tin, Raheleh Salari, Svetlana Shchegrova, Hemant Pawar, Amy L Delson, Angela DeMichele, Minetta C Liu, A. Jo Chien, Smita Asare, Cheng-Ho J Lin, Paul Billings, Alexey Aleshin, Himanshu Sethi, Maggie Louie, Bernhard Zimmermann, Laura J Esserman, Laura van 't Veer

medRxiv 2020.02.03.20019760; doi: https://doi.org/10.1101/2020.02.03.20019760
Response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT pathway dysregulation and high tumour mutational burden.
Joanne D Stockton, Louise Tee, Celina Whalley, Jonathan D James, Mark P Dilworth, Rachel Wheat, Thomas Nieto, Ian Geh, Andrew D Beggs

medRxiv 2020.02.01.20019794; doi: https://doi.org/10.1101/2020.02.01.20019794
Combinatorial benefit without synergy in recent clinical trials of immune checkpoint inhibitors
Adam C Palmer, Benjamin Izar, Peter K Sorger

medRxiv 2020.01.31.20019604; doi: https://doi.org/10.1101/2020.01.31.20019604
Incidence and Risk Factors of Second Primary Cancer after the Initial Primary Human Papillomavirus Related Neoplasms
Jiayi Shen, Huaqiang Zhou, Jiaqing Liu, Zhonghan Zhang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, Yuxiang Ma, Ting Zhou, Yaxiong Zhang, Hongyun Zhao, Yan Huang, Li Zhang

medRxiv 2020.01.29.19004507; doi: https://doi.org/10.1101/2020.01.29.19004507
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets
Sasagu Kurozumi, Mansour Alsaleem, Cintia J Monteiro, Kartikeya Bhardwaj, Stacey E P Joosten, Takaaki Fujii, Ken Shirabe, Andrew R Green, Ian O Ellis, Emad A Rakha, Nigel P Mongan, David M Heery, Wilbert Zwart, Steffi Oesterreich, Simon J Johnston

medRxiv 2020.01.24.20018622; doi: https://doi.org/10.1101/2020.01.24.20018622
STK11 and KEAP1 Mutations as Prognostic Biomarkers in an Observational Real-World Lung Adenocarcinoma Cohort
Simon Papillon-Cavanagh, Parul Doshi, Radu Dobrin, Joseph Szustakowski, Alice M Walsh

medRxiv 2020.01.23.20017566; doi: https://doi.org/10.1101/2020.01.23.20017566
Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer
Robert Wesolowski, Daniel G Stover, Maryam Lustberg, Abigail Shoben, Meng Zhao, Ewa Mrozek, Rachel M Layman, Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, Chadwick L Wright, Katharina Schregel, Susan Gillespie, Michael Berger, Andrea Camp, Jeffrey J Chalmers, Prija Balasubramanian, Brandon L Miller, Peter Amaya, Eleni Andreopoulou, Joseph Sparano, Charles L Shapiro, Miguel Angel Villalona-Calero, Susan Geyer, Alice Chen, Michael R Grever, Michael V Knopp, Bhuvaneswari Ramaswamy

medRxiv 2020.01.20.20018218; doi: https://doi.org/10.1101/2020.01.20.20018218
Immunotherapy Implication of Signature-Guided Biomarker Discovery for Trastuzumab-Resistant HER2-Positive Breast Cancer
Andrea Sand, Aspen T. Duffin, Geoffery T. Riddell, Mitchell Piacsek, Brittany Last, Chaoyang Sun, Rovin A. Richard, Judy A. Tjoe, Jun Yin

medRxiv 2020.01.17.20017947; doi: https://doi.org/10.1101/2020.01.17.20017947

Oncology

Pages